Clin2
NCT05907980Possibly a fitRecruiting

ROSE12 alone and with other drugs for advanced solid tumors

Solid Tumor

Treatments studied

Part of Cancer clinical trials.

This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
209 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must be able to take care of yourself (getting around, doing light work) – this is called an ECOG score of 0 or 1.
  • Your cancer must be advanced (has spread) and standard treatments have either stopped working, or there are no standard treatments available for you.
  • You must have a fresh tumor sample (biopsy) available, or be able to provide one for testing.
  • You cannot have significant heart or liver disease, or a history of severe immune-related side effects from a previous cancer immunotherapy.
  • You cannot have untreated or active brain metastases (cancer that has spread to the brain).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05909436Recruiting· Phase 1/Phase 2
Study GLS-012 for advanced solid tumors

This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.

Beijing
NCT07438782Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.

Philadelphia, Pennsylvania
NCT06196814Not yet recruiting· Phase 1/Phase 2
Study of a new drug plus chemo for EGFR/ALK/ROS1 lung cancer

This trial tests a new drug called AK112 combined with platinum-based chemotherapy for people with non-small cell lung cancer that has a specific gene change (EGFR, ALK, or ROS1) and has stopped responding to initial treatment. The goal is to see if this combination can help when the first targeted therapy no longer works.

NCT06923761Recruiting· Phase 1/Phase 2
Trial of a new drug for advanced solid tumors

This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.

Adelaide
NCT06884618Recruiting· Phase 1
Study of RO7673396 for advanced solid tumors with RAS mutations

This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.

Duarte, California
NCT06026501Not yet recruiting· Phase 1/Phase 2
Testing PE0116 and PE0105 for advanced solid tumors

This trial tests two experimental drugs, PE0116 and PE0105, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the combination is safe and effective for cancers like kidney, head and neck, cervical, or ovarian cancer.

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.